Pharma commercial leaders in TAs with high clinical need often tell reps to focus on efficacy and leave the coverage conversations for later. New MMIT research reveals that this approach is costing manufacturers valuable script lift. In this research paper, learn why providers are much more likely to adopt a new therapy when they understand both its clinical value and the realities of access.
